ONCT News and Press, Oncternal Therapeutics Inc. From 11/04/21

Oncternal Therapeutics (NASDAQ:ONCT): Q3 GAAP EPS of -$0.19. Revenue of $2.1M (+255.9% Y/Y) beats by $1.29M. Press Release As of September 30, 2021, we had $97.4M in cash and cash equivalents. The company believes these funds will be sufficient to fund our operations into 2023. For further ...

Progressed the development of zilovertamab (formerly cirmtuzumab) for the treatment of patients with mantle cell lymphoma, including ongoing interactions with the US FDA on potential registration pathways Identified ONCT-808 as the lead candidate for our autologous CAR-T progr...

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it has joined Karolinska Institutet’s NextGenNK Competence Center for the Devel...

Oncternal Therapeutics (NASDAQ:ONCT) announces the establishment of its Cell Therapy Scientific Advisory Board (SAB). The Cell Therapy SAB is comprised of industry and academic leaders in the cell therapy field, covering important areas of expertise including cutting edge research, preclinica...

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Cell Therapy Scientific Advisory Board (SAB). The Cell Therap...

Context Therapeutics is developing a potentially best-in-class Progesterone Receptor Antagonist that has already been validated in several female cancer indications. Biotech IPOs have accelerated throughout the pandemic with 76 companies raising in 2020 and 81 IPOs through the end of ...

SAN DIEGO, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2021 financial results after the U.S. fina...

Big Pharma has validated ROR1 therapies which are at the core of ONCT's oncology program. Despite initial enthusiasm for ONCT, the market no longer assigns any premium to its stock. Nonetheless, clinical results continue to be very positive, the company has engaged in additional p...

Today, we post our first research on a Busted IPO named Oncternal Therapeutics. The company is well funded at the moment and is focusing on advancing several candidates in its pipeline. A full investment analysis is presented in the paragraphs below. For further details see:...

Androgen Receptor (AR) inhibition is an important therapeutic approach for the treatment of Castration-Resistant Prostate Cancer (CRPC), but AR-escape mechanisms related to the expression of AR splice variants (AR-SV), such as AR-V7, represent a significant unmet need and are a key area...